Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 29


Moving Towards Minimally Invasive Genomically Based Diagnosis and Monitoring of Bladder Cancer.

Rentsch CA, Müller DC, Ruiz C, Bubendorf L.

Eur Urol. 2016 Mar 4. pii: S0302-2838(16)00240-2. doi: 10.1016/j.eururo.2016.02.050. [Epub ahead of print] No abstract available.


Dynamics of Urinary Calprotectin after Renal Ischaemia.

Ebbing J, Seibert FS, Pagonas N, Bauer F, Miller K, Kempkensteffen C, Günzel K, Bachmann A, Seifert HH, Rentsch CA, Ardelt P, Wetterauer C, Amico P, Babel N, Westhoff TH.

PLoS One. 2016 Jan 8;11(1):e0146395. doi: 10.1371/journal.pone.0146395. eCollection 2016.


Three Genes to Predict Response to Chemotherapy for Bladder Cancer: Individualised Cancer Care at the Doorstep.

Rentsch CA, Stenner F, Ruiz C, Bubendorf L.

Eur Urol. 2015 Dec;68(6):968-9. doi: 10.1016/j.eururo.2015.07.050. Epub 2015 Aug 13. No abstract available.


Early development of human lymphomas in a prostate cancer xenograft program using triple knock-out immunocompromised mice.

Wetterauer C, Vlajnic T, Schüler J, Gsponer JR, Thalmann GN, Cecchini M, Schneider J, Zellweger T, Pueschel H, Bachmann A, Ruiz C, Dirnhofer S, Bubendorf L, Rentsch CA.

Prostate. 2015 May;75(6):585-92. doi: 10.1002/pros.22939. Epub 2015 Jan 13.


Incidental prostate cancer prevalence at radical cystoprostatectomy--importance of the histopathological work-up.

Wetterauer C, Weibel M, Gsponer JR, Vlajnic T, Zellweger T, Bütikofer S, Müller G, Püschel H, Bachmann A, Gasser TC, Bubendorf L, Rentsch CA.

Virchows Arch. 2014 Dec;465(6):629-36. doi: 10.1007/s00428-014-1656-9. Epub 2014 Oct 1.


MED12 overexpression is a frequent event in castration-resistant prostate cancer.

Shaikhibrahim Z, Offermann A, Braun M, Menon R, Syring I, Nowak M, Halbach R, Vogel W, Ruiz C, Zellweger T, Rentsch CA, Svensson M, Andren O, Bubendorf L, Biskup S, Duensing S, Kirfel J, Perner S.

Endocr Relat Cancer. 2014 Aug;21(4):663-75. doi: 10.1530/ERC-14-0171. Epub 2014 Jun 17.


Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer.

Ghadjar P, Oesch SL, Rentsch CA, Isaak B, Cihoric N, Manser P, Thalmann GN, Aebersold DM.

Radiat Oncol. 2014 May 28;9:122. doi: 10.1186/1748-717X-9-122.


Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.

Rentsch CA, Birkhäuser FD, Biot C, Gsponer JR, Bisiaux A, Wetterauer C, Lagranderie M, Marchal G, Orgeur M, Bouchier C, Bachmann A, Ingersoll MA, Brosch R, Albert ML, Thalmann GN.

Eur Urol. 2014 Oct;66(4):677-88. doi: 10.1016/j.eururo.2014.02.061. Epub 2014 Mar 12.


Characterization and clinical relevance of ALDHbright populations in prostate cancer.

Le Magnen C, Bubendorf L, Rentsch CA, Mengus C, Gsponer J, Zellweger T, Rieken M, Thalmann GN, Cecchini MG, Germann M, Bachmann A, Wyler S, Heberer M, Spagnoli GC.

Clin Cancer Res. 2013 Oct 1;19(19):5361-71. doi: 10.1158/1078-0432.CCR-12-2857. Epub 2013 Aug 22.


Estrogen receptor β expression and androgen receptor phosphorylation correlate with a poor clinical outcome in hormone-naive prostate cancer and are elevated in castration-resistant disease.

Zellweger T, Stürm S, Rey S, Zlobec I, Gsponer JR, Rentsch CA, Terracciano LM, Bachmann A, Bubendorf L, Ruiz C.

Endocr Relat Cancer. 2013 May 21;20(3):403-13. doi: 10.1530/ERC-12-0402. Print 2013 Jun.


BCG-mediated bladder cancer immunotherapy: identifying determinants of treatment response using a calibrated mathematical model.

Rentsch CA, Biot C, Gsponer JR, Bachmann A, Albert ML, Breban R.

PLoS One. 2013;8(2):e56327. doi: 10.1371/journal.pone.0056327. Epub 2013 Feb 25.


Potential consequences of low biopsy core number in selection of patients with prostate cancer for current active surveillance protocols.

Müller G, Bonkat G, Rieken M, Wyler SF, Bubendorf L, Püschel H, Gasser TC, Bachmann A, Rentsch CA.

Urology. 2013 Apr;81(4):837-42. doi: 10.1016/j.urology.2012.10.068. Epub 2013 Feb 6.


Deep clonal profiling of formalin fixed paraffin embedded clinical samples.

Holley T, Lenkiewicz E, Evers L, Tembe W, Ruiz C, Gsponer JR, Rentsch CA, Bubendorf L, Stapleton M, Amorese D, Legendre C, Cunliffe HE, McCullough AE, Pockaj B, Craig D, Carpten J, Von Hoff D, Iacobuzio-Donahue C, Barrett MT.

PLoS One. 2012;7(11):e50586. doi: 10.1371/journal.pone.0050586. Epub 2012 Nov 30.


Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer.

Biot C, Rentsch CA, Gsponer JR, Birkhäuser FD, Jusforgues-Saklani H, Lemaître F, Auriau C, Bachmann A, Bousso P, Demangel C, Peduto L, Thalmann GN, Albert ML.

Sci Transl Med. 2012 Jun 6;4(137):137ra72. doi: 10.1126/scitranslmed.3003586.


Dismembered and non-dismembered retroperitoneoscopic pyeloplasty for the treatment of ureteropelvic junction obstruction in children.

Subotic S, Weiss H, Wyler S, Rentsch CA, Rassweiler J, Bachmann A, Teber D.

World J Urol. 2013 Jun;31(3):689-95. doi: 10.1007/s00345-012-0887-0. Epub 2012 May 22.


High NRBP1 expression in prostate cancer is linked with poor clinical outcomes and increased cancer cell growth.

Ruiz C, Oeggerli M, Germann M, Gluderer S, Stocker H, Andreozzi M, Thalmann GN, Cecchini MG, Zellweger T, Stürm S, Koivisto PA, Helin HJ, Gelmann EP, Glass AG, Gasser TC, Terracciano LM, Bachmann A, Wyler S, Bubendorf L, Rentsch CA.

Prostate. 2012 Nov;72(15):1678-87. doi: 10.1002/pros.22521. Epub 2012 Apr 2.


Urethral toxicity vs. cancer control--lessons to be learned from high-dose rate brachytherapy combined with intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer.

Ghadjar P, Rentsch CA, Isaak B, Behrensmeier F, Thalmann GN, Aebersold DM.

Brachytherapy. 2011 Jul-Aug;10(4):286-94. doi: 10.1016/j.brachy.2010.09.005. Epub 2010 Oct 28.


Improved detection of microbial ureteral stent colonisation by sonication.

Bonkat G, Rieken M, Rentsch CA, Wyler S, Feike A, Schäfer J, Gasser T, Trampuz A, Bachmann A, Widmer AF.

World J Urol. 2011 Feb;29(1):133-8. doi: 10.1007/s00345-010-0535-5. Epub 2010 Mar 21.


Madm (Mlf1 adapter molecule) cooperates with Bunched A to promote growth in Drosophila.

Gluderer S, Brunner E, Germann M, Jovaisaite V, Li C, Rentsch CA, Hafen E, Stocker H.

J Biol. 2010;9(1):9. doi: 10.1186/jbiol216. Epub 2010 Feb 11.


Prognostic significance of apoptotic cell death in bladder cancer: a tissue microarray study on 179 urothelial carcinomas from cystectomy specimens.

Karamitopoulou E, Rentsch CA, Markwalder R, Vallan C, Thalmann GN, Brunner T.

Pathology. 2010 Jan;42(1):37-42. doi: 10.3109/00313020903434397.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk